Benefits Realization Plan

01 Scope, and what this document does not do Boundaries

This plan covers the benefits arising from the CWP-700 Composite Wing Panel Production Program — the quality-system investment the CBA justified, the non-recurring qualification cost the TCO amortises, and the operational gains recorded in the RAIDD Log as realized decisions. It does not restate the investment case, and it does not claim a benefit has been realized where the evidence for that claim does not exist.

02 Why this program’s benefit case is shaped differently The argument

At Month 14 of 18 this program can state its cost to the dollar. The Budget is tracking $8,901,000 against baseline at zero variance, with the $383,000 management reserve held and undrawn. It cannot state its benefit at all.

Three further features distinguish this program from a business-systems program and shape everything below.

03 Benefit register 6 benefits

No benefit here is invented. Each traces to a figure or a decision already recorded elsewhere in the suite; the register’s contribution is to put them in one place and attach an owner and a measurement to each.

04 Why each benefit resists measurement — and each for a different reason Centrepiece

It would be easy to write that these benefits are “difficult to quantify” and move on. That sentence hides the useful information, which is that six benefits fail six different tests. A programme office that knows which test a benefit fails knows what to do about it; one that only knows the benefit is hard does not.

Two of those are worth drawing out, because they are the ones most likely to be reported wrongly.

BEN-01 — a zero escape count is not evidence

The temptation at closeout will be to report zero escapes as proof the quality investment paid for itself. It is not. Zero escapes is equally consistent with a quality system that caught everything it needed to and with a production run in which nothing serious went wrong anyway. To tell those apart you have to count what the system actually caught — and specifically the dispositions where the alternative to catching it was shipping it. Across the whole program the MRB handled five cases: one rework at First Article, two further reworks, one scrap and one return-to-supplier. The scrap and the return-to-supplier are the closest thing to a positive observation of BEN-01 that this program will ever produce, and there are two of them. Two observations do not establish a rate, which is precisely why the CBA argued from a break-even threshold instead of a forecast — and why BG-03 below proposes moving the escape record up to the quality system, where several programs can contribute to it.

BEN-04 — the mitigation destroyed the evidence

R-01, single-source prepreg lead time, was the highest-scored risk on the program at 9 (High/High). D-03 approved dual-source qualification. If the second source is never needed, the benefit is invisible; if it is needed, the benefit is enormous and appears as an ordinary week of production. A week of stopped line on a fixed-price contract does not save money — the fifty-person team is carried regardless, at roughly $150,115 a week against zero output, before any delivery exposure to Meridian. That figure is the exposure the decision bought down. It is not a benefit that will ever be reported, and it should not be reported as one.

05 What Purchase Order Amendment PA-002 did to this case D-06

Six days before this plan’s status date, on 3 July 2027, decision D-06 recorded Meridian’s PA-002 rate increase: a third production shift, the program from 25 people to 50, and the budget from $5,200,000 to $9,284,000. That is genuine demand growth, not a correction — and it moved the benefit case in two directions at once.

The consequence for this plan is a timing one. The CBA was written against the original configuration; PA-002 landed in the final third of the program; and the measurement regime below has 128 days to be established before the program that would establish it closes on 14 November 2027.

06 What is actually measured Leading indicators

Because four of the six benefits cannot be read in cash, the measurement regime substitutes leading indicators for lagging dollars. This is a real substitution and it costs something: leading indicators show whether the capability that produces a benefit is present, not whether the benefit occurred. That is worth accepting here, because the alternative is reporting nothing at all for five years.

Three measurement rules

• Capability is reported by shift, never only in aggregate. This mirrors the Test Strategy’s own rule for control charts, and for the same reason: a process that is capable overall while drifting on third shift is a common failure mode on a three-shift operation, and a monthly aggregate conceals it entirely. A benefit reported in aggregate inherits the same blindness.
• Every reversion from sampling to 100% inspection is recorded as a benefit event, not only as a quality event. Reversion is the mechanism by which BEN-02 gives value back. If reversions are logged only in the quality record, the benefit figure will drift upward while the underlying entitlement to it has lapsed.
• Nothing is reported as realized before the measurement window it belongs to. BEN-03 has one reading and it is binary, taken at the option decision. Reporting a proportion of it earlier would be reporting an intention.

07 Who measures after the program stops existing Handover

This is the structural problem of the whole document. Every benefit in the register realizes after Month 18, and every instrument capable of recording one is a program instrument that stops at Month 18. The RAIDD Log closes with its registers. The dashboard, the status report and the steering deck have no audience once there is no steering committee. The Closeout Report transfers steady-state support to Acme’s standing production quality organization and MRB chairmanship to the standing production Quality Review Board — a real and correct handoff, but of process, not of measurement.

08 The disclosure boundary Commercial

The TCO states a steady-state cost of $17,347 per panel and describes it, correctly, as a planning reference for Meridian’s own sourcing comparisons rather than a price Acme invoices against. That candour is appropriate between a Tier 1 supplier and an OEM, and it has a consequence that a benefits plan has to state plainly.

Reading down the register with that in mind produces an uncomfortable but useful observation: the benefits Acme keeps indefinitely are the ones that never appear as cash. Prevented escapes, supply continuity, and NDT traceability held in-house are durable precisely because they are unpriceable. The two benefits that convert cleanly to money are the two most exposed to the next negotiation. That is not an argument for concealment — a supplier whose cost position is visibly healthy is a supplier an OEM keeps — but it is an argument for deciding deliberately what is shared, rather than discovering it in a TCO written for a different purpose.

09 Open gaps 5 gaps

Recorded here with owners rather than left implicit. None is a defect in another artifact; each is something this program has not yet done.

10 Realization status at 9 July 2027 Month 14 of 18

11 Approval Governance